October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma’s synthetic ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Geron (GERN – Research Report), with a price target of ...

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer ... in the United States for the treatment of certain adult patients with lower-risk ...

Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Third Quarter 2024. At this time, all participants are in a listen-only mode. A brief question and answer session will ...

Geron Corporation ( (GERN) ) has released its Q3 earnings. Here is a breakdown of the information Geron Corporation presented to its investors.

The men and women of the armed forces have faced many fights, but in tonight’s Avera Medical Minute, we take you to Pierre to show that the power of friendship and service transcends generations.